Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01987817 · ClinicalTrials.gov registry record · Phase 2
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
A Phase 2 study of Peanut Allergy, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 8
- Study locations
NCT01987817 is a Phase 2 study of Peanut Allergy that has completed, run by Aimmune Therapeutics. The registered enrollment target is 56 participants, below the 210-participant average among 13 other Peanut Allergy trials with a reported enrollment target (73% lower). The trial reports 8 study locations across 8 states.
The verdict
NCT01987817, a Phase 2 study of Peanut Allergy, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
Conditions Studied
Interventions
- BIOLOGICAL AR101 powder provided in capsules
- BIOLOGICAL Placebo powder provided in capsules
Study Locations (8)
Arkansas
- Arkansas Children's Hospital - Little Rock
California
- UC San Diego - San Diego
Massachusetts
- Boston Children's Hospital - Boston
New York
- Mount Sinai Medical Center - New York
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- The Children's Hospital of Philadelphia - Philadelphia
Texas
- Children's Medical Center Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2014-02-06 |
| Est. Completion | 2015-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01987817
The ClinicalTrials.gov registry entry for NCT01987817 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 13 other Peanut Allergy trials with a reported enrollment target (73% lower). The listed sponsor is Aimmune Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 2 interventions - of which AR101 powder provided in capsules is the first listed.
NCT01987817 reports 8 study locations spanning 8 distinct geographic areas - top geographies include Arkansas, California, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01987817 about?
NCT01987817 is a clinical study titled "Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT". This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
What is the current status of trial NCT01987817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2014-02-06. Estimated completion is 2015-01-07.
What conditions does trial NCT01987817 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT01987817?
The interventions under investigation include: AR101 powder provided in capsules (BIOLOGICAL), Placebo powder provided in capsules (BIOLOGICAL).
Who is sponsoring clinical trial NCT01987817?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01987817 being conducted?
This trial has 8 study locations across Arkansas, California, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
-
Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy
COMPLETED · Phase 2
-
Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study
COMPLETED · Phase 2
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.